Best practices in regulation of blood and blood products
- PMID: 22122986
- DOI: 10.1016/j.biologicals.2011.11.002
Best practices in regulation of blood and blood products
Abstract
The need for blood regulation arises from the inherent risks of blood transfusion, which are minimized through implementation of standards. Regulatory oversight is advocated by the World Health Organization (WHO) as an essential element of any blood system to ensure such standards are met. The WHO Blood Regulators Network has developed "Assessment Criteria for National Blood Regulatory Systems" that describe the legal authority and functions of a fully competent blood regulator. The core functions include licensing and/or registration of blood establishments, marketing approval of blood products, oversight of all associated substances and devices, control of clinical trials, access to an independent laboratory for product assessments, lot release, and hemovigilance systems. Regulatory policy-making for blood safety is needed to address emerging threats, to consider the risks and benefits of new products and technologies, and to respond to adverse events. Structured policy-making processes are essential to ensure that decisions are science-based, with appropriate consideration of relevant economic and social factors. Decision making is especially challenging in situations of scientific uncertainty, where prudent precautionary measures may be appropriate based on assessments of risk and feasibility of meaningful interventions. There is international interest in finding a common framework for addressing blood safety decisions.
Published by Elsevier Ltd.
Similar articles
-
Alternative strategies in assuring blood safety: An overview.Biologicals. 2010 Jan;38(1):31-5. doi: 10.1016/j.biologicals.2009.10.009. Epub 2010 Jan 27. Biologicals. 2010. PMID: 20110174 Review.
-
Risk management frameworks for human health and environmental risks.J Toxicol Environ Health B Crit Rev. 2003 Nov-Dec;6(6):569-720. doi: 10.1080/10937400390208608. J Toxicol Environ Health B Crit Rev. 2003. PMID: 14698953 Review.
-
Procedures and methods of benefit assessments for medicines in Germany.Eur J Health Econ. 2008 Nov;9 Suppl 1:5-29. doi: 10.1007/s10198-008-0122-5. Eur J Health Econ. 2008. PMID: 18987905
-
The role of scientific evidence of risks and benefits in determining risk management policies for medications.Pharmacoepidemiol Drug Saf. 2004 Sep;13(9):599-608. doi: 10.1002/pds.899. Pharmacoepidemiol Drug Saf. 2004. PMID: 15362082
-
[Procedures and methods of benefit assessments for medicines in Germany].Dtsch Med Wochenschr. 2008 Dec;133 Suppl 7:S225-46. doi: 10.1055/s-0028-1100954. Epub 2008 Nov 25. Dtsch Med Wochenschr. 2008. PMID: 19034813 German.
Cited by
-
Plasma-derived medicinal products self-sufficiency from national plasma: to what extent?Blood Transfus. 2013 Sep;11 Suppl 4(Suppl 4):s132-7. doi: 10.2450/2013.019s. Blood Transfus. 2013. PMID: 24333306 Free PMC article. Review. No abstract available.
-
Stability Evaluation of National Reference Standards for Blood Products in Korea.Toxicol Res. 2017 Jul;33(3):225-231. doi: 10.5487/TR.2017.33.3.225. Epub 2017 Jul 15. Toxicol Res. 2017. PMID: 28744354 Free PMC article.
-
Implementation and performance of haemovigilance systems in 10 sub-saharan African countries is sub-optimal.BMC Health Serv Res. 2021 Nov 20;21(1):1258. doi: 10.1186/s12913-021-07235-0. BMC Health Serv Res. 2021. PMID: 34801022 Free PMC article.
-
Bridging the gap: enhancing blood regulatory functions in African contexts through comparative analysis.Front Med (Lausanne). 2025 May 1;12:1519719. doi: 10.3389/fmed.2025.1519719. eCollection 2025. Front Med (Lausanne). 2025. PMID: 40375930 Free PMC article.
-
Strengthening Blood Regulatory Systems to Tackle Africa's Unmet Needs for Blood and Blood Products.Transfus Med Hemother. 2022 Dec 22;50(2):123-128. doi: 10.1159/000528077. eCollection 2023 Apr. Transfus Med Hemother. 2022. PMID: 37066057 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous